年龄只是数字?65岁及以上肾移植受者的可及性与结局
该纵向队列研究利用UNOS、USRDS和Vizient数据,评估65岁及以上终末期肾病患者肾移植可及性与结局。结果显示该人群ESRD患病率近四倍于年轻患者,等待名单比例从1990年2%升至2025年22%,但仅占ESRD患者的43%。移植后结局和费用与年轻患者相当。
要点
- 65岁及以上ESRD患病率近四倍于年轻患者,等待名单比例增长但仍不足。
- 老年受者移植后移植物存活和总体死亡率与年轻患者相当。
- 选择性的老年受者移植围术期结局和资源使用与年轻患者相似。
核心结论
- 65岁及以上患者是ESRD增长最快的人群,肾移植可及性改善但仍不足。
- 选择性的老年受者移植结局和费用与年轻患者相当。
研究设计与样本
- 纵向队列研究,使用UNOS、USRDS和Vizient合并数据。
- UNOS纳入至2025年等待名单和移植患者,USRDS提供2020-2022年ESRD患病率,Vizient提供2022-2024年结局数据。
- 移植结局分析纳入974例患者(<65岁759例,≥65岁215例)。
主要发现
- 65岁及以上患者ESRD患病率为6.0/1000,年轻患者为1.6/1000。
- 65岁及以上患者等待名单比例从1990年2%升至2025年22%,但占ESRD患者43%。
- 老年受者BMI更低、透析时间更短、等待时间更长、糖尿病患病率更高、边缘供器官更多。
- 老年受者移植功能延迟恢复率和出院至康复机构率更高,但住院时间、并发症、再入院和费用相似。
- 移植物存活优秀且两组相当,老年受者2-3年总体死亡率略低。
临床怎么用
- 应关注老年ESRD患者肾移植可及性不足的问题。
- 选择性的65岁及以上患者可考虑肾移植,其结局和费用与年轻患者相当。
局限性
- 需要进一步研究以安全扩大该人群的肾移植可及性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Individuals 65 years of age or older represent the fastest-growing segment of the US and end-stage renal disease (ESRD) populations. This analysis assessed trends in kidney transplant (KTX) access and outcomes in patients younger than 65 vs 65 years or older. STUDY DESIGN: We conducted a longitudinal cohort study using merged United Network of Organ Sharing, United States Renal Data System, and Vizient data. United Network of Organ Sharing included patients waitlisted and transplanted at the study institution through 2025. United States Renal Data System provided ESRD prevalence (2020 to 2022), and Vizient provided outcomes data (2022 to 2024). RESULTS: ESRD prevalence was nearly fourfold higher in individuals 65 years of age or older vs younger than 65 (6.0 vs 1.6 per 1,000). The proportion of individuals 65 years of age or older added to the institutional KTX waitlist rose from 2% in 1990 to 22% in 2025, whereas they represented 43% of patients with ESRD. KTX outcomes (2022 to 2024) included 974 patients (759 younger than 65 vs 215 65 years or older). Groups were similar for sex and race or ethnicity. Patients 65 years of age or older had lower BMI, shorter dialysis duration, longer waitlist time, higher diabetes prevalence, and more marginal donor organs. Perioperative outcomes and resource use were similar. Older patients had higher rates of delayed graft function and discharge to rehabilitation but similar length of stay, complications, readmissions, and costs. Graft survival was excellent and comparable between groups. Overall mortality was very good, slightly lower at 2 to 3 years in those 65 years of age or older. CONCLUSIONS: Patients 65 years of age or older represent the fastest-growing ESRD segment. Although KTX access has improved, older patients remain underrepresented on waitlists. Outcomes and costs for select older recipients are comparable to younger patients. Further research is needed to safely expand KTX access in this population.
引用
- Nagaraju S, Taber DJ, Singh SK, et al. Is Age Just a Number? Access to and Outcomes in Kidney Transplant Recipients ≥65 Years of Age. J Am Coll Surg. 2026. PMID: 41556531. doi:10.1097/XCS.0000000000001766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。